医薬品における人工知能市場：提供、技術、展開モード、用途、エンドユーザー別-2025-2030年の世界予測

医薬品における人工知能市場は、2023年に125億8,000万米ドルと評価され、2024年には157億9,000万米ドルに達すると予測され、CAGR 26.68％で成長し、2030年には659億米ドルに達すると予測されています。

製薬業界における人工知能（AI）には、創薬の加速、臨床試験の合理化、医療の個別化、製造プロセスの強化のための高度なアルゴリズム、機械学習、データ分析の利用が含まれます。AIの必要性は、医薬品における膨大なデータと複雑性から生じ、効率を改善し、市場投入までの時間を短縮し、アンメット・メディカル・ニーズに対応するための革新的なアプローチを必要としています。その応用範囲は、疾病転帰の予測モデリングや臨床試験における患者募集の最適化から、医薬品製造における反復作業の自動化まで多岐にわたる。最終用途には、製薬会社、バイオテクノロジー企業、研究機関、競争優位のためにAIを活用しようとしているヘルスケアプロバイダーなどが含まれます。主な成長要因としては、ビッグデータの利用可能性の増大と計算能力の進歩が挙げられ、膨大なデータセットを分析して意味のある洞察を得るためのAIに対する需要を促進しています。さらに、特許切れやヘルスケアコストが迫る中、費用対効果の高い医薬品開発へのニーズが高まっていることも、AIの採用を後押ししています。精密医療、リアルタイムのデータ分析、患者エンゲージメント・プラットフォームの改善におけるAI能力の拡大にはビジネスチャンスがあります。企業は、人材獲得に投資し、戦略的提携を結び、倫理的なAI導入に重点を置くことで、これらを活用することができます。しかし、課題としては、規制上のハードル、データプライバシーに関する懸念、既存の枠組みにAIシステムを統合するための高コストなどがあります。また、AIと製薬の両方に精通した熟練専門家の人材格差もあります。AIを活用したバイオマーカー探索やバーチャルシミュレーションのためのデジタルツインなどのイノベーションは、ブレークスルーの可能性を秘めています。倫理的なAIの使用に関する調査は、市場機会を解き放つと同時に患者データを保護することができます。医薬品AI市場はダイナミックであり、規制政策、技術進歩、共同研究開発努力の影響を受けることが多いです。企業は、急速に進化する状況の中で優位に立ち続けるために、オープンイノベーションモデルと独自開発の両方を取り入れ、機敏性を維持する必要があります。

市場力学：急速に進化する医薬品における人工知能市場の主要市場インサイトを公開

医薬品における人工知能市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 治療成果を向上させるための個別化医療に対する需要の高まり
  • 既存の薬剤再利用戦略を強化するためのAI主導型アプローチの活用
  • 生物医学データおよび臨床データの処理を強化する必要性の高まり
• 市場抑制要因
  • AIソリューションの開発・導入にかかる初期投資の高さ
• 市場機会
  • 製薬業界向けの革新的なAIベースのソリューションのイントロダクション
  • AI創薬研究への多額の投資
• 市場の課題
  • データのプライバシーとセキュリティに関する懸念

ポーターのファイブフォース：医薬品における人工知能市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：医薬品における人工知能市場における外部からの影響の把握

外部マクロ環境要因は、医薬品における人工知能市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析医薬品における人工知能市場における競合情勢の把握

医薬品における人工知能市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス医薬品における人工知能市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、医薬品における人工知能市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨医薬品における人工知能市場における成功への道筋を描く

医薬品における人工知能市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 治療結果の改善に向けた個別化医療の需要の高まり
    • 既存の医薬品再利用戦略を強化するためのAI主導のアプローチの活用
    • 生物医学および臨床データの処理を強化する必要性が高まっている
  • 抑制要因
    • AIソリューションの開発と実装には多額の初期投資が必要
  • 機会
    • 製薬業界向けの革新的なAIベースのソリューションのイントロダクション
    • AI創薬調査への多額の投資
  • 課題
    • データのプライバシーとセキュリティに関する懸念
• 市場セグメンテーション分析
  • 提供内容：機能性と機能の向上により、AIベースのソフトウェアの採用が拡大
  • テクノロジー：製薬分野における機械学習技術の活用拡大
  • アプリケーション：AIソリューションによる臨床試験プロセスの効率化
  • エンドユーザー：医薬品の発見と開発のための製薬およびバイオテクノロジー企業によるAI技術の大幅な導入
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 医薬品における人工知能市場：提供別

• ハードウェア
  • メモリ
  • ネットワーク
  • プロセッサ
• サービス
  • 展開と統合
  • サポートとメンテナンス
• ソフトウェア

第7章 医薬品における人工知能市場：技術別

• コンピュータビジョン
• 機械学習
• 自然言語処理
• ロボティックプロセスオートメーション

第8章 医薬品における人工知能市場：展開モード別

• クラウドベースのソリューション
  • ハイブリッドクラウド
  • プライベートクラウド
  • パブリッククラウド
• オンプレミスソリューション

第9章 医薬品における人工知能市場：用途別

• 臨床試験
  • 臨床データ管理
  • 患者募集
  • 安全監視
• 医薬品開発
  • 処方開発
  • 前臨床研究
  • プロトタイプ設計
• 創薬
  • 薬物検査
  • リードの特定と最適化
• パーソナライズ医療
  • バイオマーカーの発見
  • ゲノム解析
  • 患者の病気の経過

第10章 医薬品における人工知能市場：エンドユーザー別

• 契約調査機関
• ヘルスケア提供者
• 製薬会社
• 調査室

第11章 南北アメリカの医薬品における人工知能市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の医薬品における人工知能市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの医薬品における人工知能市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • サノフィ、Formation Bio、OpenAIが協力し、AI統合による医薬品開発の変革を目指す
  • NVIDIA BioNeMoは、生成AIモデルで創薬を変革し、医薬品のイノベーションを加速します。
  • デンマークは画期的なNVIDIAスーパーコンピューターとの連携により医薬品分野でAIイノベーションを先導
• 戦略分析と提言

企業一覧

• AiCure, LLC
• Aspen Technology Inc.
• Atomwise Inc.
• BenevolentAI SA
• BioSymetrics Inc.
• BPGbio Inc.
• Butterfly Network, Inc.
• Cloud Pharmaceuticals, Inc.
• Cyclica by Recursion Pharmaceuticals, Inc.
• Deargen Inc.
• Deep Genomics Incorporated
• Deloitte Touche Tohmatsu Limited
• Euretos Services BV
• Exscientia PLC
• Google LLC
• Insilico Medicine
• Intel Corporation
• International Business Machines Corporation
• InveniAI LLC
• Isomorphic Labs Limited
• Microsoft Corporation
• Novo Nordisk A/S
• NVIDIA Corporation
• Oracle Corporation
• SANOFI WINTHROP INDUSTRIE
• Turbine Ltd.
• Viseven Europe OU
• XtalPi Inc.

LIST OF FIGURES

• FIGURE 1. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET RESEARCH PROCESS
• FIGURE 2. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET DYNAMICS
• TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MEMORY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NETWORK, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PROCESSOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT & INTEGRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPORT & MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HYBRID CLOUD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ON-PREMISE SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL DATA MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PATIENT RECRUITMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SAFETY MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PROTOTYPE DESIGN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY GENOMIC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PATIENT DISEASE JOURNEY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 57. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 58. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 59. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 60. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 61. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 63. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 64. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 65. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 66. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 68. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 69. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 70. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 71. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 72. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 73. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 74. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 76. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 77. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 78. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 79. ARGENTINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 81. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 82. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 83. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 84. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 85. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 86. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 88. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 89. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 90. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 91. BRAZIL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 93. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 94. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 95. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 96. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 97. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 98. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 100. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 101. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 102. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 103. CANADA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 105. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 106. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 107. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 108. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 109. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 110. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 112. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 113. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 114. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 115. MEXICO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 117. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 118. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 119. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 120. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 121. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 122. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 124. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 125. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 126. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 127. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 128. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 129. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 130. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 131. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 132. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 133. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 134. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 135. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 137. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 138. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 139. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 140. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 141. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 142. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 143. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 144. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 145. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 146. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 147. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 148. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 150. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 151. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 152. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 153. AUSTRALIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 154. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 155. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 156. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 157. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 158. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 159. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 160. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 162. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 163. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 164. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 165. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 166. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 167. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 168. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 169. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 170. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 171. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 172. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 174. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 175. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 176. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 177. INDIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 178. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 179. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 180. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 181. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 182. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 183. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 184. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 186. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 187. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 188. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 189. INDONESIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 191. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 192. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 193. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 194. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 195. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 196. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 197. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 198. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 199. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 200. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 201. JAPAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 202. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 203. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 204. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 205. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 206. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 207. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 208. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 209. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 210. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 211. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 212. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 213. MALAYSIA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 214. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 215. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 216. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 217. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 218. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 219. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 220. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 221. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 222. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 223. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 224. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 225. PHILIPPINES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 226. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 227. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 228. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 229. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 230. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 231. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 232. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 233. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 234. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 235. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 236. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 237. SINGAPORE ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 238. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 239. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 240. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 248. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 249. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 250. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 251. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 252. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 253. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 254. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 255. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 256. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 257. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 258. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 259. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 260. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 261. TAIWAN ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 262. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 263. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 264. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 265. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 266. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 267. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 268. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 269. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
• TABLE 270. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 271. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 272. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2030 (USD MILLION)
• TABLE 273. THAILAND ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 274. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 275. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
• TABLE 276. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 277. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 278. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT MODE, 2018-2030 (USD MILLION)
• TABLE 279. VIETNAM ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOU

The Artificial Intelligence in Pharmaceutical Market was valued at USD 12.58 billion in 2023, expected to reach USD 15.79 billion in 2024, and is projected to grow at a CAGR of 26.68%, to USD 65.90 billion by 2030.

Artificial Intelligence (AI) in the pharmaceutical industry encompasses the use of advanced algorithms, machine learning, and data analytics to accelerate drug discovery, streamline clinical trials, personalize medicine, and enhance manufacturing processes. The necessity for AI arises from the enormous data and complexity in pharmaceuticals, requiring innovative approaches to improve efficiency, reduce time-to-market, and address unmet medical needs. Applications range from predictive modeling of disease outcomes and optimizing patient recruitment for trials to automating repetitive tasks in drug manufacturing. End-use scope includes pharmaceutical companies, biotech firms, research institutions, and healthcare providers seeking to harness AI for competitive advantage. Key growth factors include the increasing availability of big data and advancements in computational power, driving demand for AI to analyze vast datasets for meaningful insights. Moreover, the rising need for cost-effective drug development in the face of looming patent expirations and healthcare costs further fuels AI adoption. Opportunities lie in expanding AI capabilities in precision medicine, real-time data analytics, and improving patient engagement platforms. Companies can capitalize on these by investing in talent acquisition, forming strategic alliances, and maintaining a focus on ethical AI deployment. However, challenges include regulatory hurdles, data privacy concerns, and high costs of integrating AI systems within existing frameworks. There's also a talent gap for skilled professionals adept in both AI and pharmaceuticals. Innovations in AI-driven biomarker discovery and digital twins for virtual simulations hold promise for breakthroughs. Research on ethical AI usage can safeguard patient data while unlocking market opportunity. The AI in pharmaceutical market is dynamic, often influenced by regulatory policies, technological advancements, and collaborative R&D efforts. Companies must remain agile, embracing both open innovation models and proprietary developments to stay ahead in a rapidly evolving landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Artificial Intelligence in Pharmaceutical Market

The Artificial Intelligence in Pharmaceutical Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing demand for personalized medicine to improve treatment outcomes
  • Utilization of AI-driven approaches to enhance existing drug repurposing strategies
  • Increasing need to enhance the processing of biomedical and clinical data
• Market Restraints
  • High initial investment for developing and implementing AI solutions
• Market Opportunities
  • Introduction of innovative AI-based solutions for pharmaceutical industry
  • Significant investments for AI drug discovery research
• Market Challenges
  • Concerns regarding data privacy and security

Porter's Five Forces: A Strategic Tool for Navigating the Artificial Intelligence in Pharmaceutical Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Artificial Intelligence in Pharmaceutical Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Artificial Intelligence in Pharmaceutical Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Artificial Intelligence in Pharmaceutical Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Artificial Intelligence in Pharmaceutical Market

A detailed market share analysis in the Artificial Intelligence in Pharmaceutical Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Artificial Intelligence in Pharmaceutical Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Artificial Intelligence in Pharmaceutical Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Artificial Intelligence in Pharmaceutical Market

A strategic analysis of the Artificial Intelligence in Pharmaceutical Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Artificial Intelligence in Pharmaceutical Market, highlighting leading vendors and their innovative profiles. These include AiCure, LLC, Aspen Technology Inc., Atomwise Inc., BenevolentAI SA, BioSymetrics Inc., BPGbio Inc., Butterfly Network, Inc., Cloud Pharmaceuticals, Inc., Cyclica by Recursion Pharmaceuticals, Inc., Deargen Inc., Deep Genomics Incorporated, Deloitte Touche Tohmatsu Limited, Euretos Services BV, Exscientia PLC, Google LLC, Insilico Medicine, Intel Corporation, International Business Machines Corporation, InveniAI LLC, Isomorphic Labs Limited, Microsoft Corporation, Novo Nordisk A/S, NVIDIA Corporation, Oracle Corporation, SANOFI WINTHROP INDUSTRIE, Turbine Ltd., Viseven Europe OU, and XtalPi Inc..

Market Segmentation & Coverage

This research report categorizes the Artificial Intelligence in Pharmaceutical Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Offering, market is studied across Hardware, Services, and Software. The Hardware is further studied across Memory, Network, and Processor. The Services is further studied across Deployment & Integration and Support & Maintenance.
• Based on Technology, market is studied across Computer Vision, Machine Learning, Natural Language Processing, and Robotic Process Automation.
• Based on Deployment Mode, market is studied across Cloud-Based Solutions and On-Premise Solutions. The Cloud-Based Solutions is further studied across Hybrid Cloud, Private Cloud, and Public Cloud.
• Based on Application, market is studied across Clinical Trials, Drug Development, Drug Discovery, and Personalized Medicine. The Clinical Trials is further studied across Clinical Data Management, Patient Recruitment, and Safety Monitoring. The Drug Development is further studied across Formulation Development, Preclinical Studies, and Prototype Design. The Drug Discovery is further studied across Drug Screening and Lead Identification & Optimization. The Personalized Medicine is further studied across Biomarker Discovery, Genomic Analysis, and Patient Disease Journey.
• Based on End User, market is studied across Contract Research Organizations, Healthcare Providers, Pharmaceutical Companies, and Research Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing demand for personalized medicine to improve treatment outcomes
    • 5.1.1.2. Utilization of AI-driven approaches to enhance existing drug repurposing strategies
    • 5.1.1.3. Increasing need to enhance the processing of biomedical and clinical data
  • 5.1.2. Restraints
    • 5.1.2.1. High initial investment for developing and implementing AI solutions
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of innovative AI-based solutions for pharmaceutical industry
    • 5.1.3.2. Significant investments for AI drug discovery research
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns regarding data privacy and security
• 5.2. Market Segmentation Analysis
  • 5.2.1. Offerings: Growing AI-based software adoption owing to its improved functionality & features
  • 5.2.2. Technology: Increasing utilization of machine learning technology in the pharmaceutical sector
  • 5.2.3. Applications: Improving the efficiency of clinical trial process through AI solutions
  • 5.2.4. End-users: Significant implementation of AI technologies by pharma & biotech companies for drug discovery & development
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Artificial Intelligence in Pharmaceutical Market, by Offering

• 6.1. Introduction
• 6.2. Hardware
  • 6.2.1. Memory
  • 6.2.2. Network
  • 6.2.3. Processor
• 6.3. Services
  • 6.3.1. Deployment & Integration
  • 6.3.2. Support & Maintenance
• 6.4. Software

7. Artificial Intelligence in Pharmaceutical Market, by Technology

• 7.1. Introduction
• 7.2. Computer Vision
• 7.3. Machine Learning
• 7.4. Natural Language Processing
• 7.5. Robotic Process Automation

8. Artificial Intelligence in Pharmaceutical Market, by Deployment Mode

• 8.1. Introduction
• 8.2. Cloud-Based Solutions
  • 8.2.1. Hybrid Cloud
  • 8.2.2. Private Cloud
  • 8.2.3. Public Cloud
• 8.3. On-Premise Solutions

9. Artificial Intelligence in Pharmaceutical Market, by Application

• 9.1. Introduction
• 9.2. Clinical Trials
  • 9.2.1. Clinical Data Management
  • 9.2.2. Patient Recruitment
  • 9.2.3. Safety Monitoring
• 9.3. Drug Development
  • 9.3.1. Formulation Development
  • 9.3.2. Preclinical Studies
  • 9.3.3. Prototype Design
• 9.4. Drug Discovery
  • 9.4.1. Drug Screening
  • 9.4.2. Lead Identification & Optimization
• 9.5. Personalized Medicine
  • 9.5.1. Biomarker Discovery
  • 9.5.2. Genomic Analysis
  • 9.5.3. Patient Disease Journey

10. Artificial Intelligence in Pharmaceutical Market, by End User

• 10.1. Introduction
• 10.2. Contract Research Organizations
• 10.3. Healthcare Providers
• 10.4. Pharmaceutical Companies
• 10.5. Research Laboratories

11. Americas Artificial Intelligence in Pharmaceutical Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Artificial Intelligence in Pharmaceutical Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Artificial Intelligence in Pharmaceutical Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Sanofi, Formation Bio, and OpenAI collaborate to transform drug development through AI integration
  • 14.3.2. NVIDIA BioNeMo transforms drug discovery with generative AI models to accelerate pharmaceutical innovation
  • 14.3.3. Denmark pioneers AI innovation in pharmaceuticals with groundbreaking NVIDIA supercomputer collaboration
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AiCure, LLC
• 2. Aspen Technology Inc.
• 3. Atomwise Inc.
• 4. BenevolentAI SA
• 5. BioSymetrics Inc.
• 6. BPGbio Inc.
• 7. Butterfly Network, Inc.
• 8. Cloud Pharmaceuticals, Inc.
• 9. Cyclica by Recursion Pharmaceuticals, Inc.
• 10. Deargen Inc.
• 11. Deep Genomics Incorporated
• 12. Deloitte Touche Tohmatsu Limited
• 13. Euretos Services BV
• 14. Exscientia PLC
• 15. Google LLC
• 16. Insilico Medicine
• 17. Intel Corporation
• 18. International Business Machines Corporation
• 19. InveniAI LLC
• 20. Isomorphic Labs Limited
• 21. Microsoft Corporation
• 22. Novo Nordisk A/S
• 23. NVIDIA Corporation
• 24. Oracle Corporation
• 25. SANOFI WINTHROP INDUSTRIE
• 26. Turbine Ltd.
• 27. Viseven Europe OU
• 28. XtalPi Inc.